Chimeric antigen receptor
A chimeric antigen receptor (CAR) is a genetically engineered receptor that confers a new antigen specificity on an immune effector cell.
A chimeric antigen receptor (CAR) is a genetically engineered receptor that confers a new antigen specificity on an immune effector cell. CARs are synthetic membrane proteins assembled from antibody-derived and T-cell Signaling elements. Unlike a conventional T-cell receptor (TCR), which recognizes peptide antigens presented by major histocompatibility complex molecules, a CAR generally binds a surface antigen directly through an antibody-derived recognition domain, commonly a single-chain variable fragment (scFv).
A typical CAR contains an extracellular antigen-binding domain, a hinge or spacer region, a transmembrane segment, and one or more intracellular Signaling domains. Engagement of the target antigen brings Signaling components together and can activate the engineered cell, promoting cytotoxicity, cytokine production, proliferation, and persistence. CARs are most extensively used in CAR-T cells, in which T-lymphocytes are genetically modified ex vivo and reinfused as a form of CAR-T cells. The approach has also been adapted to other immune cells, including natural-killer-cell-like systems and neutrophils.
CAR-based therapies are being investigated across hematological malignancies and solid Tumors. Their potential advantages include antigen-directed recognition that is less dependent on peptide presentation and the ability to combine tumor specificity with selected intracellular activation and costimulatory signals. Important biological and clinical considerations include tumor heterogeneity, antigen loss, limited trafficking or persistence in solid Tumors, and immune-mediated toxicities such as cytokine release syndrome. CAR designs and delivery systems are also being studied in combination with checkpoint inhibitors, bispecific engagers, and approaches intended to overcome an immunosuppressive microenvironment.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
12 papers study chimeric antigen receptor directly. The themes below are drawn from those 12.
-
Next-Generation Cancer Immunotherapy : Cancer immunotherapy is broadening beyond conventional ex vivo CAR-T cells to in vivo mRNA programming, CAR-neutrophils, and alternative antigen targets such as NKG2D. uPAR-driven fratricide and tumor-specific antibody profiling support more selective, potent cell products. 5 papers · 41.7%
-
Cell Therapies for Blood Cancers : Engineering is being used to improve cellular therapy for leukemia through site-specific integration, venetoclax priming, and selection of potent immune-cell subsets. Trogocytosis and limited persistence remain recurring barriers to antitumor activity. 4 papers · 33.3%
-
CAR-T Safety and Outcomes : Clinical assessment centers on cardiovascular events, cytokine release syndrome, neurotoxicity, and second primary malignancies after CAR-T treatment. Allogeneic CD19-directed products and Medicare-scale outcome data are extending safety evaluation beyond initial tumor response. 3 papers · 25%
Recent Findings on chimeric antigen receptor
A study in Nature Materials described an approach for generating CAR-T cells cells directly inside the body rather than relying exclusively on conventional ex vivo cell manufacture. The investigators used ERTLNPs to systemically deliver messenger RNA encoding a fibroblast activation protein–specific CAR. This delivery produced functional CAR-T cells cells in situ, and the generated cells efficiently eliminated pathological fibroblasts in models of Cancer and fibrosis while producing minimal reported off-target effects 42587055Aug. The work places CAR expression within a broader strategy of transient nucleic-acid delivery and suggests a potential route for targeting disease-associated stromal cells, rather than only malignant cells.
A preclinical study of synovial sarcoma investigated NKG2D-based CAR-T cells designed to recognize ligands of NKG2D, an activating receptor associated with Natural killer cells. The rationale was to redirect T-lymphocytes toward cells expressing NKG2D ligands, thereby applying CAR-mediated recognition to a sarcoma setting in which conventional antigen selection may be challenging 42259140Jun. The study was characterized as a proof-of-concept evaluation of this NKG2D-ligand-targeting strategy in synovial sarcoma.
Research reported in Nature Biomedical Engineering developed a modified-RNA translation platform called NeuSMRT for expression of CARs in primary neutrophils. The platform was designed to produce CAR-neutrophils in vivo for the treatment of glioma, extending CAR engineering beyond CAR-T cells and other lymphocyte-based therapies 42032037Apr. This work illustrates the use of transient RNA-based programming to confer tumor-directed functions on neutrophils and represents an alternative cellular platform for immune-cell redirection in solid Tumors.
A review addressing resistance to immune checkpoint treatment discussed CARs alongside engineered TCRs and CD3/TCR engagers as methods for imposing new tumor specificity on effector cells. In this framework, CARs are part of a broader set of cell- and molecule-based strategies intended to improve antitumor activity when checkpoint inhibitors alone are insufficient 41661081Feb. The review placed these approaches in the context of checkpoint resistance, tumor heterogeneity, and the immunosuppressive microenvironment, while also relating engineered-cell therapies to disease-specific targets such as B-cell maturation antigen (BCMA) and to safety or control strategies including inducible Caspase 9.
Written from 12 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.